Biochemically Recurrent Prostate Cancer: Superior Agents to Conventional Imaging - Andrei Iagaru

Dr. Andrei Iagaru states that the significantly changing landscape of prostate cancer diagnoses is due to new and improved imaging agents and access to resources that were once available only outside of the United State.  In this particular study, 68GA-RM2, formerly known as 68Ga-Bombesin or BAY86-7548 PET/MRI was compared to conventional imaging for patients with biochemically recurring prostate cancer. Dr. Iagaru shares specific patient outcomes that demonstrate that 68GA-RM2 is superior to other agents in diagnosing and treating the disease. 

Biography:
Dr. Iagaru is an Associate Professor of Radiology - Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford Health Care. He completed medical school at Carol Davila University of Medicine, Bucharest, Romania, and an internship at Drexel University College of Medicine, Graduate Hospital, in the Department of Medicine in Philadelphia. He began his residency at the University of Southern California (USC) Keck School of Medicine, Los Angeles, in the Division of Nuclear Medicine, where he was the chief resident. Dr. Iagaru finished his residency and completed a PET/CT fellowship at Stanford University's School of Medicine in the Division of Nuclear Medicine. His research interests include PET/MRI and PET/CT for early cancer detection; clinical translation of novel PET radiopharmaceuticals; peptide-based diagnostic imaging and therapy; and radioimmunotherapy.

Related Content:

Role of MRI in Men on Active Surveillance - Laurence Klotz

A Phase II Study of 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer

Metabolically-stabilized 68Ga-NOTA-bombesin for PET Imaging of prostate cancer and influence of protease inhibitor Phosphoramidon.

Radiopharmaceuticals for diagnosis and therapy of neuroendocrine differentiated prostate cancer.


E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe